Nurix Therapeutics, Inc.
- NRIX
- NASDAQ
- Biotechnology
- Protein Degradation/Oncology
- Small Molecule Therapeutics
$24.93
Today +2.09%Quote Oct 19, 2026, 08:00 PM UTC
−2.00%over the last month
Max drawdown −13.8%From 1-month high −2.9%3 months +6.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Nurix Therapeutics
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
Where the money comes from
Q3 2026 revenue $673.1M
- License Revenue$653.2M97.0%
- Collaboration Revenue$19.9M3.0%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
317
Founded
2009
Market value
$2.59B
Quote Oct 19
Floor
$23.73
4.8% below price
Resistance
$25.14
0.8% above price
Price vs analyst targets
19 analysts
Lowest target
$31.00Highest target
$45.00
$31.00Highest target
$45.00
- Price $24.93
- Average target $35.58
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 43% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about NRIXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free